Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥852.8B | ¥773.4B | +10.3% |
| Operating Income | ¥37.0B | ¥26.3B | +40.7% |
| Ordinary Income | ¥49.6B | ¥36.6B | +35.5% |
| Net Income | ¥36.0B | ¥24.7B | +46.1% |
| ROE | 1.3% | 0.9% | - |
Executive Summary
This earnings result achieved growth in operating income and net income exceeding the rate of revenue growth, primarily due to a significant increase in profit from the Overseas Business. Revenue was ¥852.8B (+10.3% YoY), Operating Income was ¥37.0B (+40.7%), Ordinary Income was ¥49.6B (+35.5%), and Net Income attributable to owners of the parent was ¥35.8B (+46.0%). The Operating Income margin improved to 4.3% from 3.4% in the previous year, although the Health and Food Business and Dairy Business continued to record operating losses, indicating a structure in which profit growth remains highly dependent on the Overseas Business.
Factors Affecting Earnings
【Revenue】Revenue was ¥852.8B, an increase of +10.3% YoY. The Overseas Business generated ¥264.5B (+26.9%), driving approximately 70% of the Company-wide revenue increase (+¥79.4B). In Japan, the Health and Food Business (+6.1%), Dairy Business (+2.9%), Nutritional Confectionery Business (+2.6%), and Other Domestic Businesses (+3.0%) posted moderate revenue growth, while the Food Ingredients Business declined to ¥28.5B (-2.4% YoY).
【Profit and Loss】Operating Income increased substantially faster than revenue, rising to ¥37.0B (+40.7% YoY), while the Operating Income margin improved to 4.3% from 3.4% in the previous year. Segment profit in the Overseas Business was ¥48.1B (+46.7%, 18.2% margin), exceeding consolidated Operating Income and effectively offsetting losses in the domestic Health and Food Business (-¥12.9B) and Dairy Business (-¥23.1B). Although the Nutritional Confectionery Business increased revenue, profit declined to ¥7.9B (-30.0% YoY). Ordinary Income exceeded Operating Income by ¥12.6B, supported by non-operating income of ¥19.1B, including ¥8.5B in subsidy income. Pre-tax income of ¥54.6B included extraordinary income of ¥5.0B, including a gain on the sale of investment securities of ¥4.6B; therefore, part of the increase in Net Income was attributable to temporary factors. Overall, the Company achieved increases in both revenue and profit.
Segment Analysis
The Overseas Business is a core business generating profit on a scale exceeding consolidated Operating Income, with revenue of ¥264.5B (+26.9% YoY), Operating Income of ¥48.1B (+46.7%), and a profit margin of 18.2%, improved from 15.7% in the previous year. The Nutritional Confectionery Business posted revenue of ¥154.5B (+2.6%) but recorded a decline in profit to ¥7.9B (-30.0%), reducing its profit margin to 5.1%. The Dairy Business generated revenue of ¥142.0B (+2.9%) but recorded an operating loss of ¥23.1B, with the loss remaining broadly unchanged from the previous year. The Health and Food Business generated revenue of ¥88.9B (+6.1%) but recorded an operating loss of ¥12.9B, with the loss remaining at approximately the previous year’s level despite higher revenue. The Food Ingredients Business recorded revenue of ¥28.5B (-2.4%) and profit of ¥4.9B (+20.4%, 17.2% margin), representing lower revenue but higher profit. Other Domestic Businesses generated revenue of ¥192.5B (+3.0%), with profit approximately breakeven (-¥0.03B). The concentration of consolidated profit in the Overseas Business and the continued losses in two domestic businesses are structural characteristics.
Key Financial Indicators
【Profitability】The Operating Income margin of 4.3% improved by approximately 0.9pt from 3.4% in the same period of the previous year, while the Net Income margin also increased to 4.2% from 3.2%. The gross margin was 37.6%, indicating that cost management remained at a certain level.【Cash Flow Quality】Pre-tax income of ¥54.6B included a gain on the sale of investment securities of ¥4.6B; excluding extraordinary income, the recurring level of profit was somewhat restrained. Non-operating income of ¥19.1B included ¥8.5B in subsidy income.【Investment Efficiency】ROE was 1.3% (quarterly actual result), and the low asset turnover ratio offset the benefits of improved profit margins. Against total assets of ¥3838.3B, tangible fixed assets were ¥1039.1B and investment securities were ¥586.3B, indicating a relatively asset-heavy structure and room for improvement in capital efficiency.【Financial Soundness】The Company maintained a conservative financial base, with an Equity Ratio of 72.2% and cash and deposits of ¥671.1B. Interest-bearing debt was small relative to total assets.
Cash Flow Analysis
As the Company did not disclose a cash flow statement in these results, cash trends are analyzed based on changes in the balance sheet. Cash and deposits declined to ¥671.1B from ¥686.3B in the same period of the previous year, and current assets as a whole also contracted from ¥1699.5B. Meanwhile, retained earnings increased to ¥2286.5B, suggesting that the Company retained a portion of current-period profit internally. Accounts payable and notes payable declined to ¥304.6B, indicating that shortened payment terms or restrained procurement may have affected cash management. Tangible fixed assets were ¥1039.1B, broadly unchanged from the previous year, suggesting that large-scale capital investment was limited. Overall, the Company faces limited financial constraints due to its ample cash position and low level of interest-bearing debt.
Quality of Earnings
The core source of recurring earnings was the ¥37.0B increase in Operating Income, primarily driven by profit growth in the Overseas Business, indicating good earnings quality. However, pre-tax income of ¥54.6B included extraordinary income of ¥5.0B, including a gain on the sale of investment securities of ¥4.6B; accordingly, part of the increase in Net Income to ¥35.8B from ¥24.5B in the previous year was supported by non-recurring factors. Of the ¥19.1B in non-operating income, the ¥8.5B in subsidy income may not recur every period, and this should be considered when evaluating recurring earnings power. Comprehensive income was ¥48.6B, exceeding Net Income of ¥35.8B, mainly due to a foreign currency translation adjustment of +¥9.7B. Although the gap between Net Income and comprehensive income was positive, foreign exchange factors are subject to market fluctuations and should be distinguished from sustainable earnings power.
Earnings Forecast and Guidance
The full-year plan calls for revenue of ¥3800.0B (+5.1% YoY), Operating Income of ¥140.0B (+60.2%), and Ordinary Income of ¥170.0B (+46.0%), with no revisions made during the quarter. Q1 progress ratios were 22.4% for revenue, 26.4% for Operating Income, and 29.2% for Ordinary Income, with Operating Income and Ordinary Income exceeding the simple pro rata benchmark of 25%. However, because progress in Net Income includes the gain on the sale of investment securities, achievement of the full-year plan should be assessed with greater emphasis on progress in Operating Income and Ordinary Income. Continued profit growth in the Overseas Business will be the key to achieving the full-year plan.
Shareholder Returns
The full-year dividend forecast is ¥95.00 per share, with no revision made during the quarter. This represents an increase from the previous year’s dividend result of ¥45 (estimated to be part of the combined interim and year-end dividends). Based on the full-year Net Income forecast of ¥100.0B and average shares outstanding during the period of 63.48 million shares, the Payout Ratio is calculated to be approximately in the 60% range. Given the ample cash and deposits of ¥671.1B, there is little concern regarding the Company’s ability to make dividend payments. However, as the Payout Ratio is relatively high, achievement of the full-year profit plan will affect dividend sustainability.
Risk Factors
-
Concentration of profit in the Overseas Business: Operating Income from the Overseas Business was ¥48.1B, exceeding consolidated Operating Income of ¥37.0B, creating a structure in which consolidated earnings are significantly affected by foreign exchange and market conditions in that business.
-
Deterioration in the profitability of domestic businesses: Operating losses continued in the Health and Food Business (-¥12.9B) and Dairy Business (-¥23.1B), while profit in the Nutritional Confectionery Business also declined by -30.0% YoY. If improvement in the domestic earnings structure is delayed, it could offset the benefits of profit growth overseas.
-
Dependence on temporary gains: Pre-tax income included a gain on the sale of investment securities of ¥4.6B, which contributed to full-year Net Income progress. Going forward, it will be important to monitor progress in recurring Operating Income and Ordinary Income.
Industry Benchmark (For Reference; Compiled by the Company)
Industry Benchmark (food_beverage)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income margin | 4.3% | – | – |
| Net Income margin | 4.2% | – | – |
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 10.3% | – | – |
As industry median data was not provided, a quantitative assessment of the Company’s relative positioning is not possible; however, the gross margin of 37.6% is within a generally healthy range for the food and beverage industry.
※Source: Compiled by the Company
Key Points from the Earnings Results
-
Operating Income increased by +40.7% against revenue growth of +10.3%, confirming an improvement in operating leverage. The primary driver was higher revenue and profit in the Overseas Business (revenue +26.9%, profit +46.7%).
-
Operating losses in the domestic Health and Food Business and Dairy Business continued at approximately the previous year’s levels, leaving structural improvement in the domestic businesses as a challenge for sustained expansion of consolidated earnings.
-
Progress toward the full-year Net Income forecast was 35.8%, exceeding the 25% seasonal benchmark. However, because this includes a gain on the sale of investment securities, the Operating Income progress ratio of 26.4% and Ordinary Income progress ratio of 29.2% are more representative indicators of actual progress.
Theoretical Stock Price (Reference Value)
| Scenario | Theoretical Stock Price |
|---|---|
| bear (bearish) | ¥3,703 |
| base (baseline) | ¥3,757 |
| bull (bullish) | ¥3,762 |
| Calculation Assumption | Value |
|---|---|
| Book Value Per Share (BPS) | ¥4,388 |
| Adjusted Forecast EPS | ¥172.8 |
| Cost of Equity r | 9.27% (10-year Japanese government bond 2.77% + equity risk premium 6.00% + size premium 0.50%) |
| Persistence Coefficient of Residual Income ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 60.5% |
| Forecast EPS Confidence Adjustment | ×1.100 (based on progress ahead of the full-year forecast) |
| Implied PBR / PER | 0.86x / 21.7x |
Sensitivity: ¥3,656–¥3,864 at ±1% for the cost of equity, and ¥3,737–¥3,770 at ±0.1 for ω.
Notes:
- Because progress of Net Income toward the full-year forecast (36%) exceeds the standard benchmark (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of plan tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
- Because forecast ROE is below the cost of equity, the theoretical value is below Book Value Per Share.
- Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
- Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.
(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional where necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q1 was a solid earnings release, with double-digit sales growth translating into materially faster operating and net-profit growth. Revenue increased 10.3% YoY to ¥85.28bn. Operating income rose 40.7% to ¥3.70bn, outpacing sales growth through SG&A leverage despite modest gross-margin pressure. Ordinary income increased 35.5% to ¥4.96bn. Profit attributable to owners of the parent increased 46.0% to ¥3.58bn, and EPS was ¥56.45. Gross margin declined 111bp YoY to 37.6%, as cost of sales rose 12.3%, faster than revenue. However, the SG&A ratio fell 206bp to 33.3%, more than offsetting gross-margin compression. Consequently, the operating margin expanded 94bp to 4.3%, although it remains below the 5% operating-efficiency threshold. Overseas operations were the principal earnings driver, with segment sales up 26.9% YoY to ¥26.45bn and segment profit up 46.7% to ¥4.81bn. The overseas segment generated profit exceeding consolidated operating income, highlighting that domestic loss-making businesses continue to dilute group returns. Health and food and dairy remained loss-making, while nutritional confectionery profit declined despite sales growth. Net income also benefited from ¥5.03bn of extraordinary income, including a ¥4.64bn gain on sales of investment securities, which supports reported profit but is not recurring operating performance. The annualized ROE was 5.2% and ROIC was 4.4%, indicating that earnings improvement has not yet lifted capital efficiency to a strong level. The balance sheet remains highly liquid, with a 195.4% current ratio, ¥67.11bn of cash, and only 4.2% debt-to-capital. Short-term loans rose sharply to ¥12.04bn, but cash covered short-term debt by 5.57x. Full-year guidance implies 5.1% revenue growth and 60.2% operating-income growth, and Q1 operating-income progress of 26.4% is modestly ahead of the typical 25% seasonal benchmark. The key issue for the remainder of FY2026 is whether overseas growth and domestic SG&A discipline can sustain margin improvement after excluding the securities-sale gain.
Profitability Analysis
The annualized DuPont ROE is 5.2%, decomposed into a 4.2% net profit margin, 0.889x annualized asset turnover, and 1.39x financial leverage. The low leverage factor reflects a conservative capital structure, meaning ROE is primarily constrained by modest operating profitability and a large asset base rather than financing risk. The largest operational improvement was in profitability: operating margin rose from 3.4% in the prior-year quarter to 4.3%, an expansion of 94bp. This was achieved despite gross margin falling from 38.7% to 37.6%, or 111bp of compression. Cost of sales increased 12.3% YoY, exceeding revenue growth of 10.3%, consistent with residual input-cost, manufacturing, mix, or pricing pressure. SG&A increased only 3.8% YoY to ¥28.35bn, substantially below revenue growth, reducing the SG&A ratio to 33.3% from 35.3%. Salaries and allowances increased 8.0% to ¥5.92bn, while advertising expense declined 2.4% to ¥2.49bn; advertising represented 2.9% of revenue. Segment performance was highly polarized. Overseas was the core business by operating-income contribution, producing ¥4.81bn of segment profit on ¥26.45bn of sales, for an 18.2% segment margin versus 15.7% a year earlier. Food ingredients generated ¥0.49bn of profit on ¥2.78bn of sales, a 17.6% margin, although its relatively small revenue base limits group impact. Nutritional confectionery sales increased 2.6% to ¥15.45bn, but profit fell 30.0% to ¥0.79bn and its margin declined to 5.1% from 7.5%. Health and food recorded a ¥1.29bn loss on ¥8.89bn of sales, broadly unchanged from the prior-year loss. Dairy recorded a ¥2.31bn loss on ¥14.20bn of sales, also slightly wider YoY. Domestic other sales grew 6.7% to ¥17.51bn, but the segment moved to a marginal ¥0.01bn loss from a ¥0.13bn profit. The earnings mix therefore remains dependent on the sustainability of high-margin overseas operations. The 4.3% EBIT margin and 4.4% ROIC remain below 5%, so further domestic turnaround and higher utilization of the asset base are necessary for a meaningful capital-efficiency re-rating.
Growth Assessment
Top-line growth was broad enough to support a constructive near-term demand assessment, with consolidated revenue increasing ¥7.94bn YoY. Overseas was the clear growth engine, adding ¥5.61bn of sales and accounting for roughly 71% of the consolidated revenue increase. Domestic other added ¥1.10bn of sales, while health and food added ¥0.51bn, dairy added ¥0.40bn, and nutritional confectionery added ¥0.40bn. Food ingredients declined 2.4% YoY in sales to ¥2.78bn, although its segment profit increased 20.4%. The rise in overseas sales and profit indicates favorable scale and/or mix in international markets, with a 246bp segment-margin expansion. Group operating-income growth exceeded revenue growth because SG&A growth was restrained, but the gross-margin decline shows that the improvement was not driven by stronger unit economics across the entire portfolio. Ordinary income growth lagged operating-income growth because non-operating income declined modestly YoY, although subsidy income increased to ¥0.85bn from ¥0.11bn. Full-year revenue guidance is ¥380.0bn, implying 5.1% YoY growth. Q1 revenue represents 22.4% of the full-year target, 2.6 percentage points below the standard 25% Q1 progress rate. Full-year operating-income guidance is ¥14.0bn, implying 60.2% YoY growth; Q1 progress is 26.4%, 1.4 percentage points above the standard pace. Ordinary-income progress is 29.2%, while net-income progress is 35.8%, the latter 10.8 percentage points above the standard pace and supported by the securities-sale gain. The guidance profile therefore requires continued profit acceleration through operating improvements rather than reliance on non-recurring gains. Management maintained both earnings and dividend guidance.
Financial Health
Liquidity is strong, with current assets of ¥169.95bn against current liabilities of ¥86.98bn, producing a current ratio of 195.4%. The quick ratio is also robust at 169.1%, indicating that liquidity does not depend on inventory liquidation. Working capital was ¥82.97bn. Cash and deposits of ¥67.11bn represented 17.5% of total assets and covered short-term loans by 5.57x. Interest-bearing debt totaled only ¥12.15bn, equivalent to 4.2% of capital, while interest coverage was exceptionally high at 168.05x. The reported debt-to-equity ratio was 0.39x, well below the 2.0x level associated with aggressive financial leverage. Total liabilities represented only 27.8% of total assets and owners' equity was ¥276.45bn, supporting substantial financial resilience. The principal maturity consideration is that 99.1% of interest-bearing debt is short term: short-term loans were ¥12.04bn, while long-term loans were only ¥0.11bn. This short-term funding concentration triggers a refinancing-risk alert, but its practical near-term impact is mitigated by the large cash balance and conservative debt capitalization. Short-term loans rose from ¥0.46bn a year earlier to ¥12.04bn, likely reflecting temporary working-capital or funding requirements and requiring monitoring for persistence. Accounts payable declined 31.2% YoY to ¥30.46bn, while inventories rose 7.6% to ¥22.87bn and short-term borrowing increased, which may indicate a less favorable trade-payables funding position. Investment securities of ¥58.63bn, or 15.3% of assets, provide additional balance-sheet value but also expose equity to market-price movements. Goodwill was limited to ¥1.23bn, equal to 0.4% of equity and 0.3% of assets, leaving negligible acquisition-related balance-sheet risk. Intangible assets were 6.3% of total assets, a manageable level for a branded consumer-products group.
Notable B/S Changes
Short-term loans: +¥11.99bn YoY to ¥12.04bn (+26,082.6%) - short-term funding dependence increased materially; refinancing exposure is mitigated by ¥67.11bn of cash and 5.57x cash-to-short-term-debt coverage. Accounts payable: -¥13.81bn YoY to ¥30.46bn (-31.2%) - reduced supplier financing coincided with increased short-term borrowing and should be monitored as a working-capital and cash-conversion factor. Accounts receivable: -¥10.85bn YoY to ¥39.63bn (-21.5%) - lower receivables reduce capital tied up in customer balances and partly offset inventory growth. Investment securities: +¥2.81bn YoY to ¥58.63bn (+5.0%) - the 15.3% asset weighting is material, and the Q1 securities-sale gain highlights the potential effect of portfolio transactions on earnings. Treasury stock: -¥3.14bn YoY to -¥16.74bn (+23.0% in absolute balance) - the larger treasury-share balance reduces outstanding equity capital and may support per-share metrics.
Cash Flow Quality
Operating, investing, and financing cash-flow figures are not included in the reported period data. Earnings quality can nevertheless be assessed from the income statement: profit before tax was ¥5.46bn, including ¥5.03bn of extraordinary income. The largest extraordinary item was a ¥4.64bn gain on sale of investment securities. Accordingly, reported net income of ¥3.58bn materially exceeds the level implied by recurring operating income alone. Ordinary income of ¥4.96bn was 34.1% above operating income, supported by ¥1.91bn of non-operating income, including ¥0.85bn of subsidy income, ¥0.28bn of equity-method earnings, and ¥0.16bn of interest income. The gain on securities sale is non-recurring and should be separated from assessment of ongoing earnings capacity. Working-capital indicators show accounts receivable decreased 21.5% YoY to ¥39.63bn, while inventories increased 7.6% and accounts payable declined 31.2%. The combination of lower receivables and lower payables is not, by itself, sufficient to determine cash conversion, but the decline in supplier financing and the rise in inventory warrant monitoring alongside the higher short-term borrowing. For food manufacturing, the 37.6% gross margin remains within the healthy 25-40% industry range, while the 62.4% COGS ratio remains consistent with a typical branded food-and-beverage cost structure.
Dividend Sustainability
The company maintained FY2026 dividend guidance of ¥95 per share. Based on forecast EPS of ¥157.08, the implied dividend payout ratio is 60.5%. This is slightly above the 60% benchmark commonly regarded as conservatively sustainable, but remains close to that threshold rather than indicating an excessive distribution policy. The forecast dividend requires approximately ¥6.03bn based on average shares outstanding of 63.48 million. Forecast net income attributable to owners is ¥10.0bn, providing earnings coverage of the dividend. The balance sheet provides additional support, with ¥67.11bn of cash and a low 4.2% debt-to-capital ratio. The sustainability of the policy is therefore principally tied to delivery of the ¥10.0bn full-year earnings forecast and the conversion of operating earnings into cash. Since Q1 net income was assisted by the ¥4.64bn securities-sale gain, recurring profitability rather than reported Q1 EPS should be the principal measure of dividend coverage through the remainder of the year.
Risk Assessment
Business risks include Overseas concentration: the overseas segment generated ¥4.81bn of profit, exceeding consolidated operating income of ¥3.70bn; disruption to international demand, currencies, local competition, or execution would have an outsized group impact., Domestic portfolio drag: health and food posted a ¥1.29bn loss, dairy posted a ¥2.31bn loss, and domestic other was marginally loss-making, leaving group earnings dependent on overseas profitability., Food-input and packaging-cost exposure: cost of sales grew 12.3% YoY, faster than 10.3% revenue growth, driving 111bp gross-margin compression., Consumer-products competition: nutritional confectionery sales rose 2.6%, but segment profit fell 30.0%, indicating possible pressure from product mix, promotion, pricing, or costs., Food safety, supply-chain disruption, commodity-price volatility, and changing consumer preferences remain material industry-specific risks for a branded food and beverage producer..
Financial risks include Refinancing-risk alert: 99.1% of interest-bearing debt is short term, and short-term loans increased to ¥12.04bn from ¥0.46bn YoY. Cash coverage of 5.57x and strong liquidity materially moderate the near-term risk., Investment-security exposure: ¥58.63bn of investment securities equals 15.3% of assets; the Q1 securities-sale gain demonstrates that investment-related gains can affect reported earnings., Capital-efficiency risk: annualized ROE of 5.2% and ROIC of 4.4% remain below preferred return thresholds despite the Q1 earnings recovery..
Key concerns include Operating efficiency remains low: the 4.3% EBIT margin is below the 5% alert threshold. The Q1 improvement came from SG&A leverage, but gross-margin compression limits the resilience of the operating recovery., Reported Q1 net income includes a ¥4.64bn gain on sale of investment securities, so the 46.0% YoY net-income increase overstates recurring operating momentum., The full-year operating-income forecast requires sustained margin improvement, while Q1 revenue progress was 22.4% of the annual target versus a standard 25% pace., The maintained ¥95 dividend implies a 60.5% forecast payout ratio, leaving limited room for an earnings shortfall relative to forecast..
Investment Implications
Key takeaways include Q1 operating income increased 40.7% YoY, with operating-margin expansion of 94bp to 4.3% driven by SG&A leverage., Overseas is the decisive earnings engine, delivering ¥26.45bn of revenue and ¥4.81bn of segment profit at an 18.2% margin., Domestic losses, particularly in dairy and health and food, continue to offset the profitability of overseas operations., The balance sheet is conservative, with a 195.4% current ratio, 5.57x cash-to-short-term-debt coverage, and 4.2% debt-to-capital., Q1 reported net income was boosted by a ¥4.64bn gain on sale of investment securities and should not be treated as fully recurring..
Metrics to watch include Overseas segment revenue growth and segment margin relative to the Q1 26.9% growth rate and 18.2% margin, Dairy and health-and-food segment losses, including evidence of a domestic profitability turnaround, Consolidated gross margin after the Q1 111bp YoY decline, SG&A ratio and advertising investment intensity, Short-term loan balance and the evolution of inventories and accounts payable, Progress toward FY2026 guidance of ¥380.0bn revenue, ¥14.0bn operating income, and ¥10.0bn profit attributable to owners, Recurring earnings excluding gains on sales of investment securities and subsidy income, ROIC and annualized ROE progression from 4.4% and 5.2%, respectively.
Regarding relative positioning, Glico combines a strong liquidity profile, low balance-sheet leverage, healthy branded-food gross margins, and a high-margin overseas earnings platform. Relative to stronger consumer-staples profitability profiles, however, its 4.3% operating margin, 4.4% ROIC, and 5.2% annualized ROE remain modest. The central analytical distinction is between a robust overseas franchise and domestic businesses that currently dilute consolidated returns.